hsa-miR-9-5p Down-Regulates HK2 and Confers Radiosensitivity to Nasopharyngeal Carcinoma.

Technol Cancer Res Treat

Department of E.N.T and Head and Neck Surgery, Jiujiang NO.1 People's Hospital, Jiangxi, China.

Published: November 2021

Background: This study was designed to explore the effects of hsa-miR-9-5p on radiotherapy sensitivity of nasopharyngeal carcinoma (NPC) by targeting hexokinase 2 (HK2).

Methods: The levels of hsa-miR-9-5 and HK2 in NPC patients and radiosensitive and resistant cells were determined using qRT-PCR. The dual luciferase reporter gene system was used to determine hsa-miR-9-5p targeting HK2. The level of HK2 expression in NPC were determined using qRT-PCR and western blotting after the administration of hsa-miR-9-5p agomir. The effects of hsa-miR-9-5p on proliferation and apoptosis with or without irradiation (IR) were examined using CCK-8, flow cytometry and colony formation assays. (F)-Flourodeoxyglucose uptake was used to evaluate the growth of tumor with or without radiation therapy .

Results: hsa-miR-9-5p target to inhibit HK2. Moreover, the cell proliferation was seen in a decreased trend while the cell apoptosis increased in the hsa-miR-9-5p group following radiation therapy hsa-miR-9-5p also showed a significant inhibitory effect on the growth of tumor with radiation therapy.

Conclusions: hsa-miR-9-5p improved the radiosensitivity of NPC by targeting HK2.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919207PMC
http://dx.doi.org/10.1177/1533033821997822DOI Listing

Publication Analysis

Top Keywords

hsa-mir-9-5p
9
nasopharyngeal carcinoma
8
effects hsa-mir-9-5p
8
npc targeting
8
determined qrt-pcr
8
targeting hk2
8
growth tumor
8
tumor radiation
8
radiation therapy
8
therapy hsa-mir-9-5p
8

Similar Publications

Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which may improve the diagnostic yield for MPE. Our previous study demonstrated the feasibility of isolating miRNAs from PFEVs and profiling PFEV miRNAs by Nanostring nCounter Human v3 miRNA expression assay.

View Article and Find Full Text PDF

Pre-eclampsia (PE) is a serious condition affecting 2-8% of pregnancies worldwide, leading to high maternal and fetal morbidity and mortality. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as potential biomarkers for various pregnancy-related pathologies, including PE. MiRNAs in plasma and serum have been extensively studied, but urinary miRNAs remain underexplored, especially during early pregnancy.

View Article and Find Full Text PDF

Background: Primary Sjögren's syndrome (pSS) is an autoimmune condition marked by lymphocyte infiltration in the exocrine glands. Our study aimed to identify a novel biomarker for pSS to improve its diagnosis and treatment.

Methods: The gene expression profiles of pSS were obtained from the Gene Expression Omnibus (GEO) database.

View Article and Find Full Text PDF

Background: Preeclampsia (PE) is a hypertensive disorder of pregnancy, affecting 2%-8% of pregnancies worldwide, and is the leading cause of adverse maternal and fetal outcomes. The disease is characterized by oxidative and cellular stress and widespread endothelial dysfunction. While the precise mechanisms are not entirely understood, the pathogenesis of PE is closely linked to placental dysfunction and, to some extent, syncytiotrophoblast extracellular vesicle release (STB-EVs).

View Article and Find Full Text PDF

This research provides a glimmer of hope that the knockout of HCP5 leads to a therapy response to considerably prolong the life of patients with OC. RT-PCR evaluated the expression of lncRNA HCP5 in the ovarian cancer OVCAR-3 cell line. CRISPR knockout cell lines validated by western blot.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!